Learn more about the most recent developments in the treatment of (HBR) patients with coronary artery disease through videos, interviews and panel discussions with renowned faculty from highly ranked institutions.
Key Learning Objectives
- To emphasize the importance of defining high bleeding risk in patients undergoing PCI
- To increase identification of high bleeding risk patients and learn how to apply this in your clinical practice
- To highlight the Onyx One Clinical Program, including sub-analysis and the relevance for your daily practice
More from this programme
Part 1
Ischemic and Bleeding Outcomes in Patients With vs. Without Atrial Fibrillation (AF) – insights from the Onyx ONE program
Part 2
Complex PCI with 1-month DAPT in HBR patients - insights from the Onyx ONE program
Part 3
High Bleeding Risk Patients: Identifying the ‘forgotten’ population – Do we have the tools?
Faculty Biographies
Darren Mylotte
Consultant Cardiologist
Darren Mylotte is an Irish cardiologist with specialist expertise in interventional and structural heart disease. He undertook his medical education and early professional training in Ireland before pursuing advanced subspecialty and research training in Europe. His career reflects a strong commitment to academic cardiology, combining clinical excellence with advanced research in transcatheter valve therapies.
Academic History
Dr Mylotte graduated from the Royal College of Surgeons in Ireland (RCSI) Medical School in 2001. He obtained Membership of the Royal College of Physicians in Ireland in 2004 and subsequently completed the Irish Cardiology Specialist Training Scheme.
In 2010, he was conferred with the degree of Doctor of Medicine (MD) by the Royal College of Surgeons in Ireland, based on original research. In addition to his MD, he also undertook doctoral-level research leading to a PhD focused on Transcatheter Aortic Valve Implantation (TAVI)…
David Kandzari
Director of Interventional Cardiology and Chief Scientific Officer
Dr David Kandzari obtained his undergraduate degree from Duke University School of Medicine then completed his internship and residency at The John Hopkins University School of Medicine in Baltimore, Maryland. Following his residency, he completed his general and interventional cardiology fellowship at Duke University where he joined the faculty as the John B. Simpson Assistant Professor of Interventional Cardiology and Genomic Sciences.
Dr Kandzari has held national and international leadership roles in clinical trials in cardiovascular disease and has participated in national and international program committees in cardiology. He has authored and coauthored more than 150 studies, book chapters and scientific reviews. Dr Kandzari is board certified in internal medicine and cardiovascular diseases and is certified by the Board of Interventional Cardiology. He specializes in interventional cardiology, peripheral arterial disease and cardiovascular medicine. His…